Filtered By:
Drug: Lovenox

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study Brief Reports
Conclusion— Extended-duration thromboprophylaxis with enoxaparin was associated with reduced venous thromboembolism risk and increased major bleeding in the subgroup of patients with ischemic stroke in the EXCLAIM study. Clinical Trial Registration Information— URL: http://clinicaltrials.gov. Unique Identifier: NCT00077753.
Source: Stroke - December 24, 2012 Category: Neurology Authors: Turpie, A. G. G., Hull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Chen, M., Yusen, R. D., for the EXCLAIM Investigators Tags: Cerebrovascular disease/stroke, Deep vein thrombosis, Anticoagulants Brief Reports Source Type: research

A Case of Multiple Recurrent Ischemic Stroke in a Patient with Cholangiocarcinoma and Initiation of Anticoagulation Therapy for Secondary Stroke Prevention (P4.342)
CONCLUSIONS: Initiation of anticoagulation therapy and the optimal medications for secondary stroke prevention in cancer associated stroke remain controversial. Further randomized prospective studies are needed to establish treatment guidelines.Disclosure: Dr. Cheng has nothing to disclose. Dr. Then has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Cheng, J. Z., Then, R. Tags: Cerebrovascular Case Reports Source Type: research

Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
CONCLUSIONS: -Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01583218. PMID: 27881569 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2016 Category: Cardiology Authors: Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators Tags: Circulation Source Type: research

Evaluation of Antithrombotic Bridging Methods in Acute Ischemic Stroke Patients with Atrial Fibrillation (P6.281)
Conclusions:Preliminary data supports against bridging with parenteral anticoagulation in acute ischemic stroke and AF, with a higher incidence of complications observed overall. Higher incidence of extracranial complications observed with bridging anticoagulation and higher incidence of intracranial complications observed from bridging antiplatelet therapy. This finding may be related to the limited number of patients included. A future goal for this project will be to expand the number of charts reviewed to strengthen the validity of these results.Disclosure: Dr. Swafford has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Swafford, K., Lee, J. Tags: Prevention of Cerebrovascular Disease Source Type: research

N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy
ConclusionsBaseline NT-proBNP concentration was associated with short-term stroke among patients hospitalized with acute HF. Stroke risk assessment models should consider incorporation of NT-proBNP measurement.
Source: Journal of Thrombosis and Thrombolysis - September 13, 2017 Category: Hematology Source Type: research

Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: A systematic review and meta-analysis
CONCLUSION: In patients hospitalized for acute ischemic stroke, the net clinical benefit may favor extended venous thromboprophylaxis for four to five weeks over standard thromboprophylaxis.PMID:34649783 | DOI:10.1016/j.ejim.2021.09.016
Source: European Journal of Internal Medicine - October 15, 2021 Category: Internal Medicine Authors: Emanuele Valeriani Nicola Potere Matteo Candeloro Silvia Spoto Ettore Porreca Anne Ws Rutjes Marcello Di Nisio Source Type: research

Deep Venous Thrombosis in Patients with Stroke and Intracranial Hemorrhage (P01.229)
CONCLUSIONS: Heart failure and altered level of consciousness are important risk factors for DVT/PE.Disclosure: Dr. Stecker has received royalty payments from UpToDate. Dr. Michel has nothing to disclose. Dr. Antaky has nothing to disclose. Dr. Koyfman has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Stecker, M., Michel, K., Antaky, K., Koyfman, F. Tags: P01 Cerebrovascular Disease I Source Type: research

Safe use of alteplase in a 10 months old infant with cardio-embolic stroke.
We present an infant with cardioembolic stroke treated with alteplase. He had hypoplastic left heart syndrome since birth. He underwent Norwood operation, followed by bidirectional cavopulmonary anastomosis at 3 months. On aspirin therapy he was well until heart failure developed at the age of 9 months with 2 thrombi in the right ventricle. During the course of enoxaparin therapy sudden acute left-sided haemiplegia occurred. The emergency brain CT scan was normal. Informed consent was obtained from parents after explaining the alteplase treatment protocol and possible complications. Alteplase was administered i.v. accordin...
Source: European Journal of Paediatric Neurology - April 19, 2013 Category: Neurology Authors: Rener-Primec Z, Svigelj V, Vesel S, Lovrič D, Skofljanec A Tags: Eur J Paediatr Neurol Source Type: research

Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke.
Conclusion. In cancer-associated stroke patients, treatment with enoxaparin may be more effective than treatment with warfarin for lowering the D-dimer levels. Future prospective studies are warranted to show that enoxaparin is better than warfarin for secondary prevention in cancer-associated stroke. PMID: 26064116 [PubMed]
Source: Journal of Oncology - June 15, 2015 Category: Cancer & Oncology Tags: J Oncol Source Type: research

Venous thromboembolism prevention with low molecular weight heparin may reduce hemorrhagic transformation in acute ischemic stroke
ConclusionsThis retrospective study suggests that SHPD may play a protective role in HT appearance and evolution, which requires verification by a randomized clinical trial.
Source: Neurological Sciences - March 23, 2020 Category: Neurology Source Type: research

Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients.
CONCLUSIONS: LMWH or DAT may be more effective than aspirin alone for reducing the incidence of END and ERIS within 14 days, and is associated with improved outcomes in elderly patients and those with stenosis in the posterior circulation or basilar artery at 6 months poststroke. PMID: 25628738 [PubMed]
Source: Journal of Clinical Neurology - January 31, 2015 Category: Neurology Tags: J Clin Neurol Source Type: research

Antithrombotic treatment after stroke due to intracerebral haemorrhage.
CONCLUSIONS: There is insufficient evidence from RCTs to support or discourage the use of antithrombotic treatment after ICH. RCTs comparing starting versus avoiding antiplatelet or anticoagulant drugs after ICH appear justified and are needed in clinical practice. PMID: 28540976 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 25, 2017 Category: General Medicine Authors: Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R Tags: Cochrane Database Syst Rev Source Type: research

Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States
Conclusions: Approximately 1% of patients with AIS experienced symptomatic in-hospital and/or post-discharge DVT/PE. Although 46% received prophylaxis in-hospital, only 6% received prophylaxis in the outpatient setting. This highlights the need for sustained thromboprophylaxis prescribing across the continuum of care.
Source: BMC Neurology - February 8, 2013 Category: Neurology Authors: Alpesh AminJay LinStephen ThompsonDaniel Wiederkehr Source Type: research

Low-Molecular-Weight Heparin Is More Effective Than Aspirin in Preventing Early Neurologic Deterioration and Improving Six-Month Outcome
Conclusions: For patients with acute ischemic stroke, treatment with LMWH within 48 hours of stroke until 10 days later may reduce END and deep-vein thrombosis during the first 10 days. LMWH appears to have advantages over aspirin in certain subgroups, such as elderly patients and patients with posterior circulation and basilar artery stenosis.
Source: Journal of Stroke and Cerebrovascular Diseases - March 21, 2014 Category: Neurology Authors: Xingyang Yi, Jing Lin, Chun Wang, Biao Zhang, Wanzhang Chi Tags: Original Articles Source Type: research

Serum Hepcidin Levels in Childhood-Onset Ischemic Stroke: A Case-Control Study
In this study, we aimed to estimate serum (hepcidin) level in acute ischemic stroke (AIS) patients and to investigate whether subcutaneous enoxaparin sodium, which is a low-molecular-weight heparin (LMWH) derivative, could modulate serum hepcidin level in those patients. This was a case–control study included 60 (AIS) cases, and 100 healthy children with comparable age and gender as control group. For all subjects’ serum hepcidin, interleukin-6 (IL-6), and soluble transferrin receptor [sTfR]) levels were assessed by (enzyme-linked immunosorbent assay [ELISA] method). Iron parameters including (serum iron, ferritin, tr...
Source: Medicine - March 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research